文献速递肝病消化道肿瘤与早癌

美国肝内胆管癌与肝细胞癌临床特征及结局比较

Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States.
PubMed 文献 · Hepatology · 2021-09-25

基于美国SEER 18数据库(2000-2017年)纳入13,611例iCCA和96,151例HCC患者,比较临床特征与总生存。多因素分析显示iCCA与HCC的总生存相当(aHR=1.02,95%CI 0.99-1.05),但在肿瘤≥5cm、淋巴结受累、远处转移、低分化及非治愈性治疗亚组中iCCA生存更优。

要点

  • iCCA与HCC总生存多因素分析相当(aHR=1.02,95%CI 0.99-1.05)
  • 肿瘤≥5cm、淋巴结受累、远处转移、低分化亚组iCCA生存更优
  • 非治愈性治疗亚组iCCA生存也优于HCC(aHR=0.96,95%CI 0.93-0.98)

核心结论

  • 多因素分析中iCCA与HCC的总生存相似(aHR=1.02,95%CI 0.99-1.05)。
  • 在肿瘤≥5cm、淋巴结受累、远处转移、低分化及非治愈性治疗亚组中,iCCA与更长的总生存相关。

研究设计与样本

  • 基于美国SEER 18数据库(2000-2017年)的回顾性队列研究。
  • 共纳入13,611例iCCA患者和96,151例HCC患者。
  • 采用logistic回归分析与iCCA诊断相关的因素,Cox回归评估总生存影响因素。

主要发现

  • iCCA患者中男性占50.7%,HCC患者中男性占76.3%。
  • 近期诊断、年龄<50或≥65岁、女性、非西班牙裔白人、较高收入、农村地区及较高肿瘤负荷与iCCA诊断独立相关。
  • iCCA患者总生存劣于HCC(9个月 vs 13个月;P<0.001)。
  • 多因素分析中iCCA与HCC总生存相当(aHR=1.02;95%CI=0.99-1.05)。
  • 亚组分析中iCCA在肿瘤≥5cm(aHR=0.83;95%CI=0.80-0.86)、淋巴结受累(aHR=0.76;95%CI=0.72-0.81)、远处转移(aHR=0.76;95%CI=0.73-0.79)、低分化/未分化肿瘤(aHR=0.88;95%CI=0.83-0.94)及接受非治愈性治疗(aHR=0.96;95%CI=0.93-0.98)患者中总生存更优。

关键数值与推荐

  • iCCA与HCC总生存多因素比较的aHR=1.02(95%CI=0.99-1.05)。
  • 肿瘤≥5cm亚组aHR=0.83(95%CI=0.80-0.86),淋巴结受累亚组aHR=0.76(95%CI=0.72-0.81)。
  • 远处转移亚组aHR=0.76(95%CI=0.73-0.79),低分化/未分化亚组aHR=0.88(95%CI=0.83-0.94)。
  • 非治愈性治疗亚组aHR=0.96(95%CI=0.93-0.98)。

临床怎么用

  • 对于具有肿瘤≥5cm、淋巴结受累、远处转移、低分化或仅接受非治愈性治疗等不良预后特征的原发性肝癌患者,iCCA诊断可能提示相对更好的生存。
  • 在解读iCCA与HCC生存比较时需考虑分期、治疗等混杂因素,多因素校正后总体生存差异消失。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Intrahepatic cholangiocarcinoma (iCCA) and hepatocellular carcinoma (HCC) are the most common primary liver cancers (PLCs). Differences in their clinical features and outcomes are open for investigation in a large-scale study. We aim to investigate the differences in clinical features and outcomes between iCCA and HCC. APPROACH AND RESULTS: The Surveillance, Epidemiology, and End Results Program 18 Database (2000-2017) was used to extract demographic and clinical features of HCC and iCCA patients. Logistic regression analysis was performed to identify factors associated with iCCA diagnosis versus HCC. Cox regression analysis was used to assess factors affecting overall survival (OS). There were 13,611 iCCA and 96,151 HCC patients. Half of iCCA (50.7%) and three quarters of HCC (76.3%) patients were male. Diagnosis in recent year, age (<50 or ≥65), female sex, non-Hispanic White race, higher income, rural area, and higher tumor burden were independently associated with iCCA diagnosis versus HCC. Patients with iCCA had worse OS than those with HCC (9 vs. 13 months; P < 0.001). However, OS was comparable between iCCA and HCC in multivariable analysis (adjusted hazard ratio [aHR] = 1.02; 95% CI = 0.99-1.05). In subgroup analyses, iCCA was associated with better OS than HCC in patients with tumor ≥5 cm (aHR = 0.83; 95% CI = 0.80-0.86), lymph node involvement (aHR = 0.76; 95% CI = 0.72-0.81), distant metastasis (aHR = 0.76; 95% CI = 0.73-0.79), poorly/undifferentiated tumors (aHR = 0.88; 95% CI = 0.83-0.94), and those receiving noncurative treatment (aHR = 0.96; 95% CI = 0.93-0.98). CONCLUSIONS: We identified the demographic, socioeconomic, and clinical features associated with iCCA diagnosis over HCC among patients with PLC. Although iCCA patients presented at an advanced stage, OS was similar between iCCA and HCC in multivariable analysis. iCCA was associated with longer OS for subgroups with poor prognostic features.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Lee YT, Wang JJ, Luu M, et al. Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States. Hepatology. 2021. PMID: 34114675. doi:10.1002/hep.32007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。